


## Original Article

# Acute Traumatic Subdural Hematoma and Anticoagulation Risk

Maryam Kia<sup>1</sup>, Rajeev Singh Saluja<sup>1,2</sup> and Judith Marcoux<sup>1,2</sup> 

<sup>1</sup>Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada and <sup>2</sup>Department of Neurosurgery, McGill University Health Centre, Montreal, QC, Canada

**ABSTRACT: Background:** Anticoagulation is used to prevent thromboembolic events. It is a common practice to hold anticoagulation in the first few days following a traumatic brain injury (TBI) with intracranial hemorrhage. However, traumatic subdural hematomas (SDH) are prone to re-hemorrhage long after the trauma. Data are scarce in the literature on the best timing to resume anticoagulation following a TBI. **Methods:** Review of 95 consecutive patients admitted to a level 1 trauma center with a diagnosis of traumatic SDH and requiring anticoagulation. The reasons for anticoagulation, the amount of time without anticoagulation, CT characteristics, and the incidence of thromboembolic events or SDH re-hemorrhage were collected. **Results:** 41.3% used anticoagulation for coronary artery disease and peripheral vascular disease, 24% for atrial fibrillation, 12% for cardiac valve replacement, and 12% for venous thromboembolic events. Anticoagulation was held a median of 67 days. For most patients (82.1%), anticoagulation was re-introduced once the SDH had completely resolved. For 17.9%, anticoagulation was restarted while the SDH had not completely resolved. One (1.1%) patient suffered from an atrial clot while anticoagulation was held. For those with residual SDH, 41.2% suffered from a SDH re-hemorrhage and 17.6% required surgery. The risk of re-hemorrhage climbed to 62.5% if the SDH remnant was large. **Conclusion:** Anticoagulation while there is a residual SDH was associated with a significant risk of re-hemorrhage. This risk should be weighed against the risk of holding anticoagulation.

**RÉSUMÉ :** L'hématome sous-dural traumatique aigu et les risques de l'anticoagulothérapie. **Contexte :** L'anticoagulothérapie vise à prévenir les événements thromboemboliques, mais il est pratique courante de suspendre le traitement durant les premiers jours qui suivent un trauma crânien (TC), accompagné d'une hémorragie intracrânienne. Toutefois, les hématomes sous-duraux (HSD) traumatiques sont susceptibles de nouvelles hémorragies longtemps après le trauma. Par ailleurs, il existe peu de données, dans la documentation médicale, sur le moment le plus propice de la reprise du traitement anticoagulant à la suite d'un TC. **Méthode :** L'étude consistait en un examen de 95 dossiers de patients consécutifs, admis dans un centre de traumatologie de niveau I après avoir subi un HSD traumatique et traités par les anticoagulants. Des données ont été recueillies sur les motifs de l'anticoagulation, la durée de l'arrêt temporaire de l'anticoagulothérapie, les caractéristiques de la tomodensitométrie (TDM) et l'incidence des événements thromboemboliques ou des nouvelles hémorragies liées aux HSD. **Résultats :** Dans l'ensemble, 41,3 % des patients prenaient des anticoagulants pour des coronaropathies ou des maladies vasculaires périphériques; 24 %, pour de la fibrillation auriculaire; 12 %, pour des remplacements de valvules cardiaques et 12 %, pour des thromboembolies veineuses. L'anticoagulothérapie a été interrompue durant une période médiane de 67 jours. Chez la plupart des patients (82,1 %), il y a eu reprise du traitement après la disparition complète de l'HSD; chez les autres (17,9 %), le traitement a été repris même si l'HSD ne s'était pas complètement résorbé. Un patient (1,1 %) a subi un événement thromboembolique par suite d'un caillot auriculaire formé durant cette période d'arrêt temporaire du traitement anticoagulant. Enfin, parmi les patients ayant un HSD résiduel, 41,2 % ont subi une nouvelle hémorragie liée à l'HSD et 17,6 % ont dû être opérés. Quant à ceux chez qui l'HSD résiduel était volumineux, le risque de nouvelle hémorragie a grimpé jusqu'à 62,5 %. **Conclusion :** L'anticoagulothérapie a été associée à un risque significatif de nouvelle hémorragie dans les cas d'HSD résiduel. Aussi faudrait-il évaluer les risques de la poursuite du traitement anticoagulant contre ceux de son interruption temporaire.

**Keywords:** Traumatic brain injury; Head trauma; Brain injury; Subdural hematoma; Anticoagulation

(Received 26 June 2021; final revisions submitted 23 November 2021; date of acceptance 22 December 2021; First Published online 3 January 2022)

## Introduction

The population in developed countries is growing older. In our own level 1 trauma center, the proportion of patients suffering from a traumatic brain injury (TBI) aged 70 years or older went from 18% in 2000 to 48.5% in 2012.<sup>1</sup> Older victims of trauma also

often have significant co-morbid medical conditions and may be taking medications that can further complicate injury and resuscitation. Anticoagulants are frequently used in this age group for various indications. This class of medication poses a particular challenge to neurosurgeons in the setting of a TBI, as the clinician

**Corresponding author:** Judith Marcoux, Neurosurgeon, Montreal General Hospital, McGill University Health Centre, 1650 Cedar ave, room L7-516, Montreal, Quebec, Canada, H3G 1A4. Email: [judith.marcoux@mcgill.ca](mailto:judith.marcoux@mcgill.ca)

**Cite this article:** Kia M, Saluja RS, and Marcoux J. (2023) Acute Traumatic Subdural Hematoma and Anticoagulation Risk. *The Canadian Journal of Neurological Sciences* 50: 188–193, <https://doi.org/10.1017/cjn.2021.518>

© The Author(s), 2022. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation.

is caught between “a rock and a hard place”: anticoagulants may exacerbate intracranial hemorrhage, while their abstinence may lead to thromboembolic complications.

Atrial fibrillation is the commonest indication for anticoagulation therapy. Indeed, atrial fibrillation is associated with an increased risk of embolic stroke, particularly when associated with other risk factors.<sup>2</sup> The CHADS2 scoring system gives points to specific risk factors. Warfarin can decrease the annual risk of stroke by half, from low to high CHADS2 scores.<sup>3</sup> Anticoagulants are also the mainstay of treatment for deep venous thrombosis (DVT), which, if not treated can lead to pulmonary embolism (PE) and post-phlebotic syndrome. It is also used to prevent DVT and PE in high-risk patients. Another common indication for anticoagulation is a metallic cardiac valve. A meta-analysis including 13,088 patients and studying 53,647 patient-years found that anticoagulation decreases the risk of valve thrombosis from 1.7% to 0.2%/year and decreases the risk of embolism from 4 to 1%/year. It also found that mitral valves have 5 times the risk of valve thrombosis and 1.5 times the risk of major embolism compared with aortic valves.<sup>4</sup>

Acute TBI is well known to be associated with abnormal coagulation parameters,<sup>5</sup> especially within the first 24-48 hours. Expansion of intracerebral contusions and subdural hematomas, as well as extra-dural hematomas, is a common phenomenon in the first few hours to days after a TBI. Therefore, it is a universal practice to avoid anticoagulation medications in the first 24-48 hours following a TBI with intracranial bleed. Being on an anticoagulant also significantly increases the mortality of a traumatic intracranial bleed,<sup>6-7</sup> while rapid reversal of anticoagulation therapy decreases the mortality.<sup>8</sup> After the acute period, the risk of intracranial hemorrhage expansion decreases sharply. However, a category of intracranial hemorrhage is prone to recurrent hemorrhages and expansion long after the trauma. Indeed, traumatic subdural hematoma (SDH) can enlarge and become symptomatic weeks and even months after a TBI, with a rate of significant spontaneous re-hemorrhage of 5%.<sup>9</sup> Only one study looked specifically at the risk of SDH expansion with antithrombotic medication.<sup>10</sup> Both anticoagulant and antiplatelet aggregation therapy were included, and it was restarted at a mean of 9 days post-admission, with a risk of significant intracranial hemorrhage expansion of 9%. Another study looked at the risk of rebleed with intracranial hemorrhages in previously anticoagulated patients, with some having resumed anticoagulation but it did not detail the specific risk of rebleeding for traumatic SDH while anticoagulated. However, SDH showed a significant risk of rebleed, anticoagulated or not (15%) and patients with intracranial hemorrhages also had a significant risk of rebleed when fully re-anticoagulated (20% vs 6%).<sup>11</sup>

The absence of guidelines is apparent when the neurosurgeons need to make a decision about patients suffering from a traumatic SDH and concomitantly requiring anticoagulation therapy. The goal of this study is to provide a better assessment of the actual risk of re-hemorrhage for patient suffering from traumatic SDH when anticoagulation therapy is initiated and balance it with the risk of withholding anticoagulation therapy.

## Methods

### Study population

All patients admitted to the Montreal General Hospital, an adult tertiary trauma center (level 1), with a diagnosis of traumatic SDH between January 2006 and January 2013 and prescribed anticoagulant therapy pre- or post-injury were considered for the

study. First, the TBI program Database and the Trauma Registry Database were used to identify all patients admitted with a diagnosis of traumatic SDH. Second, a retrospective study of all charts (in-patient hospital charts and out-patient clinic notes) was performed to identify all those who were on anticoagulant therapy at the time of the injury and those who required anticoagulant therapy after the injury. Third, patients were excluded if (1) they died within 14 days of their admission due to the severity of the initial trauma, and if their death was unrelated to either post-trauma administration or withholding of anticoagulant therapy; (2) there was no indication for anticoagulation pre-injury *and* the indication post-injury came after a complete radiological resolution of the traumatic SDH; (3) the SDH was not traumatic; (4) the SDH was not acute; only patients presenting with an acute SDH were included in the study; (5) there was no SDH (incorrectly coded); or (6) charts were missing or incomplete after multiple attempts to locate them. The institutional Research Ethics Board reviewed and approved this study.

### Patient management

All patients with a traumatic SDH were evaluated by a trauma team and by the neurosurgery service. Patients requiring immediate surgery, according to the Brain Trauma Foundation guidelines, were directed to the operating room. Therefore, patients with a symptomatic SDH greater than 10 mm and/or with an associated midline shift greater than 5 mm, patients with decreasing GCS score or showing signs of herniation or with increased intracranial pressure (ICP) in relation to the SDH were treated surgically.<sup>12</sup> According to the guidelines and the attending neurosurgeon's clinical judgment, patients with small SDH, patients with asymptomatic SDH, or very elderly patients with minimal symptoms were treated conservatively. All patients treated conservatively were admitted to the intensive care unit under observation. All patients presenting with an INR above 1.4 received prothrombin complex to reverse the effect of warfarin. All patients with a GCS of 8 or less and an abnormal scan had an ICP monitor placed, according to the 2007 Brain Trauma Foundation guidelines.<sup>13</sup> Prophylactic anticoagulation was initiated in non-ambulatory patients 48 to 72 hours after the trauma, provided there was stability of the intracranial hemorrhagic lesions on two consecutive CT scans.<sup>14</sup> Patients with non-surgical SDH upon admission with delayed clinical deterioration and with chronicization and volume expansion of the SDH were also treated surgically, by burrhole evacuation when amenable to it, or by craniotomy. Anticoagulation was resumed according to the following institutional protocol: patients with no residual SDH were simply started back on warfarin with bridging until a therapeutic INR was reached with low-molecular-weight heparin, except for cardiac valvular replacement patients; they were bridged on intravenous unfractionated heparin instead. Patients with a residual SDH were started on intravenous unfractionated heparin at a lower PTT target with no bolus injection. A CT head was done after 48 to 72 hours to verify if there was any new bleed. If no new bleed was detected, the patient was started on warfarin and switched to low molecular weight heparin as a bridging therapy, except for patients with cardiac valvular replacement. Those patients were kept on intravenous unfractionated heparin while warfarin was added until the INR was therapeutic.

CT scans were also performed 3-4 weeks after the traumatic event and every month afterwards as surveillance. Any new neurological symptom also prompted a CT scan.

### Data collected

We first collected demographic data (age and gender) and injury-related data (mechanism of trauma, initial GCS score, injury severity score (ISS)).<sup>15</sup> We also collected data known to have influence on the rate of SDH re-hemorrhage (history of falls, alcohol abuse history).<sup>9</sup> The following imaging characteristics of the SDH on CT scan were also collected: SDH maximal thickness and location (convexity, parafalcine, tentorial, or posterior fossa). The specific anticoagulant agents as well as the medical indications for anticoagulation were recorded. The number of surgical evacuations and the type of evacuation (burrhole or craniotomy) done prior to starting/restarting anticoagulant therapy was noted.

We recorded how long the anticoagulant was held post-injury when patients were anticoagulated prior to their injury. We also looked at the CT scan characteristics of the SDH at the time of anticoagulation re-introduction and divided the patients into 2 groups: in the first group, the SDH had already completely resolved at the time of anticoagulation therapy resumption; in the second group, SDH remnant was still present. The quality of the remnant SDH could include acute re-hemorrhage, subacute, or chronic. These remnants were also subdivided into 2 groups, in order to see if the size of the remnant had an incidence on the risk of re-hemorrhage, with a “large” remnant being 5 mm or more in thickness and more than 3 cm in length and a “small” or “focal” remnant being less than 5 mm in thickness and 3 cm or less in length.

### Outcome measures

The primary outcome measures were (1) the rate of adverse events related to the withholding of anticoagulation therapy (DVT, PE, stroke, transient ischemic attack, myocardial infarction, etc. . . .); (2) the number of SDH re-hemorrhages while anticoagulated. A SDH was considered to have re-hemorrhaged if there was on CT scan a new hyperdense component to the subdural collection. Fluid expansion alone was not considered a re-hemorrhage. The need for a surgical intervention due to the re-hemorrhage was also recorded.

### Statistics

Descriptive statistics were reported for all variables as means and standard deviations for numerical variables, and percentages for categorical data. Chi-square test was used for comparisons.

### Results

#### Patients sample and characteristics

The MGH TBI and Trauma Registry databases contained 1919 patients coded as “traumatic SDH” for the study time period. We found 137 patients who were on anticoagulant prior to the traumatic event. Forty-five patients were excluded because they died early from the severity of the injury (25), the SDH was not acute (15), or there was insufficient data (5). There were also three cases where anticoagulation therapy was not used before the traumatic SDH but was initiated post-trauma for DVT in two cases and DVT and PE in 1 case. A total of 95 patients were therefore included.

Seventy-one (75%) were male and 24 (25%) were female. The mean age was 74.4 with a standard deviation of 12 years and a range between 19 and 94. A majority of patients (83.2%) were aged 65 years and over. The mean GCS on admission was 13.4

**Table 1:** Glasgow Coma Scale score on admission

GCS	N (total = 95)	%
15	48	50.5
14	25	26.3
13	5	5.3
9-12	7	7.4
3-8	10	10.5

GCS = Glasgow Coma Scale score; N = number of subjects; % = percentage of the sample.

**Table 2:** Mechanism of injury

Mechanism of injury	N (total = 95)	%
FFOH	81	85.3
FFH	6	6.3
MVA	1	1.1
PED	5	5.3
Bike	1	1.1
other	1	1.1

FFOH = fall from own height; FFH = fall from height; MVA = motor vehicle accident; N = number of subjects; PED = pedestrians hit by a car; % = percentage of the sample.

(see table 1 for the breakdown of GCS). The great majority (82.1%) of patients suffered from a mild TBI (GCS between 13 and 15). The ISS was, however, 25.7 on average, ranging from 16 to 50. Table 2 details the mechanisms of injury. Ten patients (10.5%) were found to have a history of alcohol abuse, while 22 subjects in the sample (23.2%) had a history of recurrent falls.

#### Imaging characteristics

The SDH on admission had a mean thickness of 11.5 mm, ranging from 1 to 43 mm, and a median of 10 mm. The majority (56.8%) measured 10 mm or less. The location of the SDH was as follows: 84 (88.4%) at the convexity, 7 (7.4%) tentorial, and 4 (4.2%) parafalcine.

#### Surgical treatment

Fifteen patients required an urgent evacuation of their SDH by craniotomy in the acute setting and another 3 required craniectomy along with the evacuation of the SDH. Fifteen patients underwent burrhole evacuation of their SDH in a delayed fashion once it became more chronic, prior to the institution or re-introduction of therapeutic anticoagulation.

#### Anticoagulation therapy

Table 3 summarizes the reasons for anticoagulation therapy prior to the injury. All but one patient used warfarin, with the remaining one using dabigatran. A significant number of patients (29 patients; 31.5%) also used antiplatelet aggregation agents in combination with warfarin (24 used acetylsalicylic acid, 3 used clopidogrel, and another 2 used acetylsalicylic acid and clopidogrel along with warfarin).

**Table 3:** Rationale for anticoagulation therapy

Rationale	N	
	Total = 92	%
Atrial fibrillation	23	24
Cardiac valve prosthesis	11	11.9
Previous DVT/PE	11	11.9
Chronic heart failure	3	3.3
Pace Maker	6	6.5
CAD and PVD	38	41.3

CAD = coronary artery disease; DVT = Deep venous thrombosis; N = number of subjects; PE = pulmonary embolism; PVD = peripheral vascular disease; % = percentage of the sample.

### Timing of therapeutic anticoagulation re-introduction and complications

Anticoagulation therapy was held an average of 105.6 days and a median of 67 days (range 0-868 days). During the time therapy was held, there was one adverse event recorded (1.1%): a patient with previous mitral valve replacement was found to have an atrial clot on surveillance echocardiogram at 10 days following reversal and withdrawal of warfarin therapy. Therapeutic anticoagulation was reinitiated thereafter, and the patient did not develop embolic complication.

For the majority of patients (78 patients-82.1%), therapeutic anticoagulation was re-introduced when the SDH had completely disappeared at follow-up CT scan. For 17 patients (17.9%), therapeutic anticoagulation was restarted while the SDH had not completely resolved on CT scan. The residual was qualified as small in 9 patients and as large in 8 patients. In the group with a large residual, two patients (25%) had a significant re-hemorrhage requiring surgical evacuation; another 3 patients (37.5%) suffered from re-hemorrhage but did not require surgery; however, anticoagulation therapy was held again. In total, 62.5% in that group suffered from a re-hemorrhage. In the group with a small remnant, 2 patients (22.2%) had a re-hemorrhage, with one of the 2 (11.1%) requiring neurosurgical intervention. A large remnant was associated with an increased risk of re-hemorrhage ( $P = 0.04$ ). For the entire group with a residual SDH, 41.2% (7 patients) suffered a SDH re-hemorrhage with 17.6% (3 patients) requiring surgical intervention. One patient remained with mild expressive dysphasia after a re-hemorrhage, despite surgical evacuation of the expanding SDH. The remaining dysphasia, however, was mild.

### Discussion

The present study gives information about the risk of anticoagulation therapy for patients with traumatic SDH. Traumatic intracerebral contusion, subarachnoid hemorrhage, or epidural hematoma do not tend to progress after a few days post-injury and most expert will agree that initiating anticoagulation therapy after about one week post-injury is safe in regards to the TBI. SDH, however, presents a challenge to the clinician when patients are on anticoagulants, as SDH tends to re-hemorrhage long after the initial event.<sup>9</sup> Anticoagulants are commonly used, and their beneficial effects in preventing thromboembolic events are well documented, especially for patients with mechanical cardiac valves<sup>4</sup> or atrial fibrillation.<sup>3</sup> However, these pathologies are more common in the elderly population – a population that is also at

increased risk of falls and TBI. Gaining a better knowledge on the safest use of anticoagulant in traumatic SDH is therefore of prime importance.

Our study showed that a temporary interruption of anticoagulant therapy, for an average duration of 105.6 days and a median of 67 days, led to a 1.1% thromboembolic complication rate. The complication was reversible in that particular patient. It also showed that initiation of anticoagulant therapy, while the SDH is still not completely resolved, is associated with a risk of re-hemorrhage of 41.2% and a risk of requiring a surgery of 17.6%. This risk is 3.5 times higher than if there was no anticoagulant therapy when comparing the rate of re-hemorrhage in a cohort study from our institution (5%).<sup>9</sup> For one patient (5.9%), there was permanent but mild neurological deficit related to the re-hemorrhage. The risk of re-hemorrhage was significantly higher if the residual SDH was large compared to small.

Many studies have looked at anticoagulation in neurosurgical pathologies, but only a few have looked at TBI.<sup>10,16-19</sup> The American Heart Association and the American Stroke Association Stroke Council formulated guidelines for patients with *spontaneous* intracranial hemorrhage and stated that anticoagulation interruption for 7 to 10 days did not result in thromboembolic complications and was therefore safe.<sup>20</sup> The guidelines do not refer to traumatic lesions, however, and while many TBI patients are in a hypocoagulable state, some patients are hypercoagulable in the acute setting. Furthermore, the risk of re-hemorrhage is not addressed. A recent study showed that the probability of having thromboembolic complications in patients with high risks factors (high CHADS2 score or mechanical heart valves) was non-existent for the first 7 days without anticoagulation. The risk however increased from 0% at 7 days to 10.5% at 14 days, and at 38.5% at 30 days. This study included only 6 SDH, and the anticoagulants were held for an average of 57 days. There is no mention of the status of the SDH at the time of anticoagulation resumption.<sup>17</sup> Pandya et al. included 55 patients with SDH and anticoagulation or antithrombotic therapy. They showed 9.1% risk of “clinically significant” hematoma expansion when anticoagulation or antithrombotic therapy was initiated within 14 days of admission. The size of the SDH at the time of anticoagulation initiation was not mentioned, and the total observation time was also not mentioned.<sup>10</sup> Another study included 11 chronic SDH, where anticoagulation was held from less than 3 days to more than 1 month. None of the SDH re-hemorrhaged; however, there was, once again, no more information on the status of the SDH at the time of anticoagulation resumption.<sup>18</sup>

Wijdicks et al.<sup>19</sup> looked at patients anticoagulated for mechanical heart valves and with intracranial hemorrhage. Thirty-nine patients were included, among which 20 had acute SDH, 10 had lobar hematomas, 4 had subarachnoid hemorrhage, 3 had cerebellar hematomas, and 2 had basal ganglionic hematomas. Thirteen patients died within 2 days from their intracerebral hemorrhage while the remaining 26 had no thromboembolic events for the duration of anticoagulation therapy interruption, which lasted on average 8 days and ranged from 2 days to 3 months. Wijdicks et al.<sup>19</sup> therefore suggested that a temporary interruption of anticoagulation, including aggressive reversal upon presentation, in those patients with intracranial hemorrhage and mechanical heart valves with no history of systemic embolization was safe. Their recommendation was that a discontinuation of anticoagulation for 1 to 2 weeks should be considered to follow the evolution of the hematoma. No patient developed expansion of their intracranial hemorrhage once anticoagulation had been restarted, but SDH patients were not separately analyzed and there was no mention on the amount of residual hematoma either.

Another study looked at TBI patients specifically and post-traumatic DVT and PE. Byrnes et al.<sup>16</sup> found 42 patients for which anticoagulation was indicated to treat post-traumatic thromboembolic events. Twenty-six were anticoagulated, while 16 were not. The average timing to start anticoagulation was 12 days post-trauma, with 23 % receiving anticoagulation within 1 week of the trauma, and 31% after 2 weeks only. Half of the 26 patients (13) had an initial diagnosis of SDH. None of the SDH expanded in that study; however, the size of the SDH at the time of initiation of anticoagulation is again not mentioned.

All the studies presented had a relatively small number of patients with traumatic SDH (6, 11, 20 and 13).<sup>16-19</sup> Our study has the largest sample in the literature so far on the one type of intracranial traumatic pathology (SDH) that causes the main dilemma. Our study showed a high risk of SDH re-hemorrhage with anticoagulation, while none of the previously mentioned studies had SDH re-hemorrhage. The timing of anticoagulation resumption varied in those studies from a few days to many weeks. The average delay for SDH in Jung et al.<sup>17</sup> was 57 days. However, none of the mentioned studies described the abnormalities on brain CT at the time of anticoagulation therapy resumption. There was also no description of how the follow-up and the detection of re-hemorrhage was done. Our study is the first to clearly show that the amount of time elapsed since stopping anticoagulation therapy is not as important as whether the SDH has resolved or not.

The guidelines from the American Heart Association and the American Stroke Association Stroke Council stipulated that interrupting anticoagulation for 7 to 10 days was safe for patients with indications for anticoagulation.<sup>20</sup> Another study on prosthetic heart valve found that 2 weeks of anticoagulation interruption did not result in adverse events,<sup>21</sup> while another study including patients at high risk found that the probabilities of having thromboembolic complications increased with time (0.0% at 7 days, 10.53% at 14 days, and 38.49 at 30 days).<sup>17</sup> Our study had only 1.1% occurrence of thromboembolic complication, despite a prolonged interruption in anticoagulation for many patients. This could be explained by the fact that many of our patients did not have a strong indication for anticoagulation, or were not at high risk. Similar rates of thromboembolic events were reported in studies on chronic subdural and patients on antithrombotic agents prior to presentation and surgery.<sup>22-23</sup>

### Limitations of the study

The main limitation of this study lies in the fact that it is a retrospective study. Some cases could have been missed simply because documentation and history taking was not thorough. Likewise, the CHADS2 scores were not well documented in the patients' cohort and therefore could not be used to judge the exact risk of thromboembolic events in patients anticoagulated for atrial fibrillation. Also, some patients were lost to follow-up and could not be included; although since the cohort was mainly composed of elderly patients and patients with chronic medical diseases who have regular medical follow-up, the number of patients who did not come for follow-up remained relatively low (4 patients-4.2% of the cohort). Therefore, an inclusion bias towards patient who had complications might have occurred. Likewise, the possibility of an acute and severe deterioration leading to death in patients lost to follow-up cannot be excluded, particularly if patients presented to an outside facility and were never transferred to our institution. Finally, the number of patients with residual SDH who were

treated with anticoagulants is very small, and therefore, results can easily be skewed.

### Recommendations

For the majority of the patients, the safest course is to wait until the SDH has resolved before initiating anticoagulant therapy. However, the SDH should be closely followed so that the medication can be started as soon as possible. A CT scan can be done as early as 1-2 weeks post-injury for small SDH. Larger SDH may take somewhat longer to resolve but the majority will have resolved by 2-3 months, since half of the cohort had a normalized CT by 67 days. Some patients required a much longer time for their SDH to resolve but for some others in our cohort, the follow-up could have been done earlier.

Patients at higher risk of thromboembolic events, such as those with higher CHADS2 score, or metallic mitral valve replacement will be harder to manage. A re-hemorrhage in the SDH may have less dramatic consequences than a large territory stroke. It might therefore be wise to restart anticoagulation earlier, combined with a close follow-up of the SDH. These patients could also benefit from follow-up cardiac ultrasound to detect the presence of an atrial clot or a thrombosed valve. This is what was done for the patient in our cohort who was found to have an atrial clot. Fortunately, it was diagnosed before sending emboli and causing a potentially devastating stroke. However, one must not forget that if there is a SDH re-hemorrhage, anticoagulation therapy will often have to be held again and perhaps for a longer period. An aggressive approach to the SDH with surgical evacuation to reduce the time delay for its resolution might be justified in some patients, provided that their surgical risk is not too high. This approach was also suggested by Kawamata et al.<sup>18</sup>

### Conclusion

This study on the risk of anticoagulation therapy in the setting of traumatic SDH shows that while a SDH is still present, the risk of re-hemorrhage is 41.2%, and the risk of requiring a surgery for the re-hemorrhage is 17.6%. The risk of re-hemorrhage increases when the residual SDH is larger. Withholding anticoagulant therapy for a median of 67 days was associated with a 1.1% incidence of adverse thromboembolic events. Regular imaging to follow the SDH regression, as well as close monitoring of patients with higher risk of thromboembolic events is warranted.

**Acknowledgments.** The authors would like to thank Dr Abdullah Al-Kuweiti for his initiative in the project, Mrs. Mitra Feyz and Mrs. Johanne Prudhomme for their help with the database, the archivists for their time and effort, and Dr Mohammad Maleki for caring for these patients.

**Disclosure of Interest.** Rajeev Singh Saluja has received stat up funds from the Research Institute of McGill University Health and the Neurosurgery Department Practice Plan; none of those funds were used for the preparation of the present manuscript. He has also received payment for medico-legal expertise from The Canadian Medical Protection Association and from the Boro Gordon Frigon and Jones Law Firm, but none of those payments have any link to the present manuscript. The other authors have no conflict of interest to report.

**Statement of Authorship.** Maryam Kia collected and analyzed data, drafted the manuscript, and critically reviewed it.

Judith Marcoux supervised the project, collected data, and completed the manuscript.

Rajeev Singh Saluja critically reviewed the manuscript.

## References

1. de Guise E, LeBlanc J, Dagher J, et al. Trends in hospitalization associated with TBI in an urban level 1 trauma centre. *Can J Neurol Sci.* 2014;41:466–75.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. *JAMA.* 2001;285:2864–70.
3. Stroke Prevention Atrial Fibrillation III Writing Committee. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. *JAMA* 1998;279:1273–7.
4. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prosthesis. *Circulation.* 1994;89:635–41.
5. Laroche M, Kutcher ME, Huang MC, Cohen MJ, Manley GT. Coagulopathy after traumatic brain injury. *Neurosurgery.* 2012;70:1334–45.
6. Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. *J Trauma.* 2006;60:553–7.
7. Mina AA, Knipfer JF, Park DY, Bair HA, Howells GA, Bendick PJ. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. *J Trauma.* 2002;53:668–72.
8. Ivascu FA, Howells GA, Junn FS, Bair HA, Bendick PJ, Janczyk RJ. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. *J Trauma.* 2005;59:1131–7.
9. Bajsarowicz P, Prakash I, Lamoureux J, et al. Nonsurgical acute traumatic subdural hematoma: what is the risk? *J Neurosurg.* 2015;123:1176–83.
10. Pandya U, Pattison J, Karas C, O'Mara M. Does the presence of subdural hemorrhage increase the risk of intracranial hemorrhage expansion after the initiation of antithrombotic medication? *Am Surg.* 2018;84:416–21.
11. Hawryluk GW, Uastin JW, Furlan JC, Lee JB, Kelly CO, Fehlings MG. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. *J Thromb Haemost.* 2010;8:1500–8.
12. Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. brain trauma foundation. chapter 4: guidelines for the surgical management of traumatic brain injury. *Neurosurgery.* 2006;58:S16–24.
13. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury. VI. indications for intracranial pressure monitoring. brain trauma foundation; american association of neurological surgeons; congress of neurological surgeons. Joint Section on Neurotrauma and Critical Care. *J Neurotrauma.* 2007;24:S37–44.
14. Dudley RR, Aziz I, Bonnici A, et al. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits. *J Neurotrauma.* 2010;27:2165–72.
15. Baker SP, O'Neill B, Haddon W Jr. Long WB: the injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. *J Trauma.* 1974;14:187–96.
16. Byrnes MC, Irwin E, Roach R, James M, Horst PK, Reicks P. Therapeutic anticoagulation can be safely accomplished in selected patients with traumatic intracranial hemorrhage. *World J Emerg Surg.* 2012;7:25. DOI 10.1186/1749-7922-7-25.
17. Jung HS, Jeon IC, Chang CH, Jung YJ. Effect of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. *J Korean Neurosurg Soc.* 2014;55:69–72.
18. Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K. Management of intracranial hemorrhage associated with anticoagulant therapy. *Surg Neurol.* 1995;44:438–42.
19. Wijdicks EF, Schievink WI, Brown RD, Mullany CJ. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. *Neurosurgery.* 1998;42:769–73.
20. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults : 2007 update : a guideline from the american heart association/American stroke association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group : the american academy of neurology affirms the value of this guideline as an educational tool for neurologists. *Circulation.* 2007;116:e391–e413.
21. Ananthasubramaniam K, Beattie JN, Rosman HS, Jayam V, Borzal S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? *Chest.* 2001;119:478–84.
22. Guha D, Coyne S, Macdonald RL. Timing of resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study. *J Neurosurg.* 2016;124:750–9.
23. Zhang JY, Aw NMY, Tan CH. Impact of time to resumption of antithrombotic therapy on outcomes after surgical evacuation of chronic subdural hematoma: a multicenter cohort study. *J of Clin Neurosci.* 2021;89:389–96.